Frequently Asked Questions

What is the goal of the Davos Alzheimer’s Collaborative (DAC)?

DAC is a pre-competitive coalition focused on driving global, cross-sector scientific, business, policy and financial coordination in Alzheimer’s preparedness. Our long-term vision is the creation of a global ecosystem of innovation that speeds up and scales the global response to Alzheimer’s disease and changes its trajectory for good.

Where did the idea of DAC originate and why is it important to the future of innovation in Alzheimer’s Disease?

The idea for DAC began at the Lausanne Workshop – the world’s leading forum on Alzheimer’s innovation. Leaders and experts from across sectors posed a simple question: where can we significantly move the needle in the next five years? The answer came a month later at the Davos World Economic Forum Meeting 2020, where DAC was conceived by private-sector executives, government leaders, NGOs and healthcare thought leaders. Since then, DAC has grown into a 6-year, ~$700 million plan to speed innovation in Alzheimer’s and overcome barriers to finding a cure.

How does DAC plan to change the trajectory of Alzheimer’s Disease?

DAC is focused on three areas of highest unmet need that are essential to making faster progress toward the discovery, testing and delivery of precision interventions for Alzheimer’s. Global Cohort Development: DAC will work to increase targets for drug development and identify associated biomarkers to enable better understanding of the heterogeneity and the variability of Alzheimer’s etiology. Global Clinical Trials Support Platform: DAC will work to create a platform to support global clinical trials that reduce the cost and time to bring new treatments to market. Healthcare System Preparedness: DAC will work to ensure healthcare system readiness for broad access to new Alzheimer’s therapies.

What is the five-year vision for each of the DAC focus areas?

Global Cohort Development: By 2025, and with the partnership of International HundredK+ Consortium Cohort (IHCC), DAC aims to build a diverse cohort of five million people with or at risk for Alzheimer’s disease. The cohort will be linked by an integrated target discovery platform and biosample repositories relevant across central nervous system (CNS) diseases.

Global Clinical Trials Support Platform: By 2025, DAC aims to build a global clinical trial network that spans the transatlantic and includes engagement with Japan, Australia, China, Colombia and South Korea. The network will:

• Develop public and private trials that adapt evidence-based techniques for improved trial efficiency.
• Deploy a biomarker-based recruitment program, database mining technology and a trial ready network of AD clinical trial sites.
• Achieve targeted savings in time per study and savings per study to exceed 6 months and $10 to $20 million, respectively.
• Create a convening mechanism to share insights globally.

Healthcare System Preparedness: By 2025, DAC aims to have helped facilitate the implementation of global commitments and strategies made by G20, G7 and international organizations to foster collaboration, provide better care today and ensure access to future innovations in treatment and care.

Who is involved in DAC?

DAC is convened by The Global CEO Initiative on Alzheimer’s Disease (CEOi) and the World Economic Forum (WEF). It is led and funded by global experts from government, industry and philanthropy.

For more information about the Davos Alzheimer’s Collaborative, our seed funders and our expert advisors, please visit www.davosalzheimerscollaborative.org.